{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016078",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016078_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"solriamfetol\" outputclass=\"int-heading-drug\">Solriamfetol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Solriamfetol   is predicted to   increase   the risk of a hypertensive crisis when given with   isocarboxazid .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016079",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016079_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"solriamfetol\" outputclass=\"int-heading-drug\">Solriamfetol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Solriamfetol   is predicted to   increase   the risk of a hypertensive crisis when given with   phenelzine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016080",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016080_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"solriamfetol\" outputclass=\"int-heading-drug\">Solriamfetol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping <ph otherprops=\"rasagiline\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/rasagiline.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3114\">rasagiline</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Solriamfetol   is predicted to   increase   the risk of a hypertensive crisis when given with   rasagiline .  Manufacturer advises avoid and for 14 days after stopping  rasagiline .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016081",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016081_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"solriamfetol\" outputclass=\"int-heading-drug\">Solriamfetol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping <ph otherprops=\"safinamide\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/safinamide.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP213016\">safinamide</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Solriamfetol   is predicted to   increase   the risk of a hypertensive crisis when given with   safinamide .  Manufacturer advises avoid and for 14 days after stopping  safinamide .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016082",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016082_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"solriamfetol\" outputclass=\"int-heading-drug\">Solriamfetol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping <ph otherprops=\"selegiline\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/selegiline-hydrochloride.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3116\">selegiline</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Solriamfetol   is predicted to   increase   the risk of a hypertensive crisis when given with   selegiline .  Manufacturer advises avoid and for 14 days after stopping  selegiline .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016083",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2#bnf_i1643858016083_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"solriamfetol\" outputclass=\"int-heading-drug\">Solriamfetol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Solriamfetol   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				}
			],
			"hasSearchLabel": " Solriamfetol  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/solriamfetol-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Solriamfetol </title>"
			},
			"rdfs:label": "solriamfetol"
		}
	]
}